Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
出版年份 2019 全文链接
标题
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-11-12
DOI
10.3389/fimmu.2019.02664
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure
- (2019) Olivia M. Lucero et al. BRITISH JOURNAL OF HAEMATOLOGY
- CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
- (2019) Hong Qin et al. Science Translational Medicine
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Jiang Cao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL Into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT)
- (2018) Haneen Shalabi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
- (2018) Franziska Blaeschke et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
- (2018) Dok Yoon et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia
- (2018) Jaclyn Rosenthal et al. AMERICAN JOURNAL OF HEMATOLOGY
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
- (2018) Edward A. Clark et al. Frontiers in Immunology
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
- (2018) Haiying Qin et al. Molecular Therapy-Oncolytics
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
- (2017) Jeannette Fischer et al. JOURNAL OF IMMUNOTHERAPY
- Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression
- (2017) Prajna Guha et al. JOURNAL OF LEUKOCYTE BIOLOGY
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
- (2017) J Pan et al. LEUKEMIA
- Fully human CD19-specific chimeric antigen receptors for T-cell therapy
- (2017) D Sommermeyer et al. LEUKEMIA
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Molecular basis of human CD22 function and therapeutic targeting
- (2017) June Ereño-Orbea et al. Nature Communications
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Erratum: Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
- (2017) Shu Su et al. Scientific Reports
- Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
- (2017) Hamid R. Mirzaei et al. Frontiers in Immunology
- MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
- (2017) Amanda C. Winters et al. Frontiers in Pediatrics
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- (2016) Elias Jabbour et al. CANCER
- Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis
- (2016) Daichi Inoue et al. GENES & DEVELOPMENT
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
- (2016) Fabiana Perna et al. Translational Cancer Research
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
- (2016) Marco Ruella et al. Computational and Structural Biotechnology Journal
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Inhibitory receptors as targets for cancer immunotherapy
- (2015) Meghan E. Turnis et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
- (2015) Tengfei Zhang et al. Oncotarget
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Effector-Mediated Eradication of Precursor B Acute Lymphoblastic Leukemia with a Novel Fc-Engineered Monoclonal Antibody Targeting the BAFF-R
- (2014) R. Parameswaran et al. MOLECULAR CANCER THERAPEUTICS
- T-Cell Immunotherapy: Looking Forward
- (2014) Jacqueline Corrigan-Curay et al. MOLECULAR THERAPY
- Cancer treatment: The killer within
- (2014) Heidi Ledford NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
- (2013) Harjeet Singh et al. PLoS One
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
- (2013) Zakaria Grada et al. Molecular Therapy-Nucleic Acids
- Inhibitory Receptors on Lymphocytes: Insights from Infections
- (2012) P. M. Odorizzi et al. JOURNAL OF IMMUNOLOGY
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies
- (2011) H. Singh et al. CANCER RESEARCH
- Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies
- (2011) Partow Kebriaei et al. HUMAN GENE THERAPY
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started